Allergan, Inc. v. Sandoz, Inc. et al, No. 2:12-cv-00207 (E.D. Tex. Sept. 30, 2016)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Before the Court are the competing motions for summary judgment by Plaintiff Allergan Sales, LLC (“Allergan”) and Defendants Sandoz, Inc., Alcon Laboratories, Inc., Alcon Research, Ltd., and Falcon Pharmaceuticals, Ltd. (collectively “Sandoz”) (Dkt. No. 277; Dkt. No. 280; Dkt. No. 281). Allergan’s motion sought summary judgment that Sandoz was precluded from challenging the validity of claim 4 of U.S. Patent No.